about
Management of bleeding and coagulopathy following major trauma: an updated European guideline.Clinical review: Traumatic brain injury in patients receiving antiplatelet medicationThe European guideline on management of major bleeding and coagulopathy following trauma: fourth editionUse of recombinant factor VIIa (rFVIIa) as pre-hospital treatment in a swine model of fluid percussion traumatic brain injuryRecombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use.Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indicationsManagement of bleeding following major trauma: an updated European guideline.Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleedingOptimizing the use of blood products in trauma care.Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trialsUse of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding.Recombinant factor VIIa in the treatment of non-hemophiliac bleeding.Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experienceThe safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients.Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.Preclinical trauma studies of recombinant factor VIIa.Recombinant activated factor VIIa and hemostasis in critical care: a focus on traumaManagement of bleeding following major trauma: a European guideline.The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trialPro/con debate: does recombinant factor VIIa have a role to play in the treatment of patients with acute nontraumatic hemorrhage?Hemorrhagic shock in obstetrics.Interventional Algorithms for the Control of Coagulopathic Bleeding in Surgical, Trauma, and Postpartum Settings: Recommendations From the Share Network GroupEffect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven)Pharmacologic interventions for the management of critical bleeding.Overview of the human pharmacokinetics of recombinant activated factor VII.Hemostatic therapy for the treatment of intracranial hemorrhage.Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice.Hemostatic and neuroprotective effects of human recombinant activated factor VII therapy after traumatic brain injury in pigs.Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.The contemporary role of blood products and components used in trauma resuscitation.Update and new developments in the management of the exsanguinating patient.Resuscitative strategies to maintain homeostasis during damage control surgery.Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case reportUncontrolled haemorrhage in pelvic fracturesd---Can the inevitable be avoided?Goals of therapy in common bleeding emergencies.Protocol-driven approach of bleeding abdominal and pelvic trauma.Recombinant-activated factor VII in patients with uncontrolled bleeding: A retrospective observational analysis.Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective.Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
P2860
Q21092902-53284A45-F298-48F0-A9B8-C52DDA19F77AQ26830409-7EC5AB91-AFE2-4C60-B822-5F47025BE61AQ27339343-253BE100-5FC0-4493-8760-E98709A4459CQ33581052-9D054751-74B5-42D6-B8EC-F92955189041Q33633854-88C79C9F-E9EC-445B-A7E8-73960FD86697Q33876266-8A96078E-E561-4C91-9CE0-9D7B04B2BB9BQ33919178-B92DA0B8-DDD2-4D9E-AC3A-DAAB2613C900Q35544621-8CC47DF4-3B6C-44A2-ACD4-5DF1E48A8CEBQ35578932-CC43C9E6-478D-49EC-89E9-7BABFB363894Q35629970-B4ECE303-4B0D-4F66-977C-5F639FB78F90Q35998366-933CDB0E-6FD8-4C0F-8EEF-88496F9C6F97Q36077574-C9D2CDA8-0BC4-4D72-B8BD-39870B90D250Q36082357-BDF26A60-47F3-4B92-B0CE-266DF3B40771Q36150578-C9B2EA12-5EA2-4CB4-B65A-55A9D26D4DB2Q36284640-D6722F4F-62D6-433C-BA02-402AC067AD7AQ36284643-BF546F76-4CFD-487D-BE39-FFFDAC35D7F1Q36284647-22B6A399-B3D8-454D-A8E0-12F744848840Q36296517-1ACC13F5-848D-4DB9-8408-C805D2FA65C1Q36349573-69CE09FB-7FB6-45F9-8C2D-AF70D9C310B4Q36392691-A08C61E8-365C-4F9F-BD68-BA3ED04B7194Q36500606-74316EC4-7470-471E-B964-24637C2F5762Q36541979-8811C0B5-D408-4CA6-8786-22B6502565D4Q36543599-05A989FF-34E3-4FDD-A366-D473D806BCB3Q36839258-68AD013E-7E72-4133-ABB7-403BF9FB1749Q36920723-7AAFCA64-9876-42D0-9AA5-549E7A85D985Q36981748-EBAB0ACC-8ED5-4DE9-952F-116D7BFAA8BAQ37117872-9DE1D785-7736-404D-B940-07F1070706E2Q37210021-8E567B35-9851-485D-BE38-70FF2FBE2A13Q37691716-1C43FBA9-907D-4362-A101-1D1635176AC3Q37731832-02DB4815-E2E0-4474-ACB4-6A5B19AF2782Q37812157-445E97F2-0506-41E7-B227-C7E78C26233AQ37900080-78449FF3-8B42-43BF-B88C-D86F1A0C6DC1Q37996338-49A00A4D-4226-47EF-A108-9CAAF9E0D493Q41820542-48B96685-3EF7-4EE8-AAFA-0606B44FF805Q41856593-4798DDDD-DAA2-4D55-B86D-CDC9D836DC51Q42008295-A93D315B-F44F-4FAB-9172-B38BAEBE8F87Q42070728-5CB907C8-6B18-453C-A114-76AA7F6B95A4Q42143401-1CCE14E9-1141-4545-B2D6-10B18F338514Q43055091-6FCE6905-DBEE-4507-8642-0595684E652FQ44637329-BD90C5A4-6BD3-497E-B149-044752C34A66
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Factor VIIa for correction of traumatic coagulopathy.
@en
Factor VIIa for correction of traumatic coagulopathy.
@nl
type
label
Factor VIIa for correction of traumatic coagulopathy.
@en
Factor VIIa for correction of traumatic coagulopathy.
@nl
prefLabel
Factor VIIa for correction of traumatic coagulopathy.
@en
Factor VIIa for correction of traumatic coagulopathy.
@nl
P2093
P1433
P1476
Factor VIIa for correction of traumatic coagulopathy.
@en
P2093
James O'Connor
John R Hess
Mary Hyder
Matthew D'Angelo
Maureen McCunn
Richard P Dutton
Thomas M Scalea
P304
709-18; discussion 718-9
P356
10.1097/01.TA.0000140646.66852.AB
P407
P577
2004-10-01T00:00:00Z